"初診受付時間：8:45～11:30 休診日：第2・4土曜日、日曜日、祝日、年末年始 当院の初診受診は原則として他院からの診療情報提供書（紹介状）が必要です。 また、ご予約が必須の診療科などもございますので、ご来院前にホームページを必ずご確認ください。"

During the past decade, Kitano Hospital conducted 19 clinical trials. In the 10-year time frame, 19 clinical trials started and 12 clinical trials were completed, i.e. on average, 63.2% percent of trials that started reached the finish line to date. In the past 5 years, 11 clinical trials started and 8 clinical trials were completed. i.e. 72.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Kitano Hospital" #1 sponsor was "Pfizer" with 6 trials, followed by "Hoffmann-La Roche" with 4 trials sponsored, "Bayer" with 3 trials sponsored, "Boehringer Ingelheim" with 3 trials sponsored and "Kyoto University" with 3 trials sponsored. Other sponsors include 14 different institutions and companies that sponsored additional 22 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Kitano Hospital" #1 collaborator was "JANSSEN Alzheimer Immunotherapy Research & Development, LLC" with 3 trials as a collaborator, "Eli Lilly and Company" with 2 trials as a collaborator, "Maruishi Pharmaceutical" with 2 trials as a collaborator, "Tokyo Medical and Dental University" with 2 trials as a collaborator and "American College of Rheumatology" with 1 trials as a collaborator. Other collaborators include 4 different institutions and companies that were collaborators in the rest 14 trials.

According to Clinical.Site data, the most researched conditions in "Kitano Hospital" are "Gastric Cancer" (3 trials), "Alzheimer's Disease" (2 trials), "Anemia" (2 trials), "Colorectal Cancer" (2 trials) and "Diabetic Macular Edema" (2 trials). Many other conditions were trialed in "Kitano Hospital" in a lesser frequency.

Most popular intervention types in "Kitano Hospital" are "Drug" (32 trials), "Other" (6 trials), "Procedure" (5 trials) and "Biological" (3 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (11 trials), "Faricimab" (4 trials), "Sham Procedure" (4 trials), "ACC-001" (3 trials) and "Aflibercept" (2 trials). Other intervention names were less common.

The vast majority of trials in "Kitano Hospital" are 36 trials for "All" genders and 2 trials for "Female" genders.

Currently, there are NaN active trials in "Kitano Hospital". undefined are not yet recruiting, 4 are recruiting, 5 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 25 completed trials in Kitano Hospital, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Kitano Hospital, 1 "Phase 1" clinical trials were conducted, 9 "Phase 2" clinical trials and 25 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".